Simply chose your treatment, fill in the online questionnaire and complete the checkout process.
Once our prescriber approves your order we dispense and prepare your medication.
We then dispatch your order and have it delviered to you so you can sit back and relax while we take care of your medication needs.
Registered Pharmacy. based in Central London
All our medicines are sourced from MHRA apprroved suppliers.
We are fully insured by the National Pharmacy Assoiciation
Wide Range of Treatments
Same Day Delivery Options
Secure & Discreet Treatments
Arexvy is a vaccine used to protect against respiratory syncytial virus (RSV) in adults aged 60 and over. RSV can cause severe respiratory illnesses, particularly in older adults and those with pre-existing health conditions.
Arexvy is recommended for adults aged 60 years and older. In the UK, eligibility may be determined based on risk factors, such as chronic respiratory, cardiovascular, or immunosuppressive conditions, following guidance from healthcare professionals.
Arexvy stimulates the immune system to produce antibodies that fight against RSV. This helps prevent serious illness by reducing the chances of developing severe respiratory complications.
Arexvy is given as a single injection, typically into the upper arm (deltoid muscle). Depending on individual health circumstances and recommendations from health authorities, a booster dose may be required in the future.
Most people experience mild side effects, including:
Serious side effects from Arexvy are rare, but like all vaccines, it may cause allergic reactions. Symptoms of an allergic reaction include difficulty breathing, swelling of the face or throat, or hives. Seek medical attention immediately if you experience any severe reactions.
You should not receive Arexvy if you:
Yes, Arexvy can be administered alongside other vaccines, including the flu and pneumococcal vaccines, as long as they are given in different injection sites. It is recommended to consult with a healthcare provider for personalised advice on co-administration.
Currently, Arexvy is recommended as a single dose for RSV prevention in adults aged 60 and over. However, future booster doses may be recommended, depending on evolving guidelines from health authorities like the NHS and information from studies.
Clinical studies have shown that Arexvy is highly effective in reducing the risk of severe RSV infection in older adults. Its effectiveness is especially pronounced in individuals with underlying health conditions that increase the risk of complications from RSV.
Availability of Arexvy on the NHS may vary depending on local guidelines and individual risk factors. Your GP or healthcare provider can offer guidance on whether you qualify for the vaccine and how to access it.
The duration of protection is still being studied, but current data suggest that it provides significant immunity for at least one RSV season. Booster doses may be recommended based on evolving guidance from health authorities.
For more detailed guidance on Arexvy, consult your GP or refer to the NHS website and the "Green Book," which offers comprehensive information on vaccines and immunisation in the UK.
Always consult with your healthcare provider to ensure the vaccine is suitable for your individual health circumstances.